H.R. 3680 — what changed

changed In general— Not later than six months after the date of the enactment of this Act, the Secretary of Health and Human Services shall may establish, in accordance with this section, a four-year co-prescribing five-year opioid overdose reversal drugs prescribing grant program (in this Act referred to as the “grant program”) under which the Secretary shall provide not more than a total of 12 grants to eligible entities to carry out the activities described in subsection (c).program”).

changed Eligible entity— For purposes of this section, the term eligible entity means a federally qualified health center (as defined in section 1861(aa) of the Social Security Act (42 U.S.C. 1395x(aa)), an opioid treatment program under part 8 of title 42, Code of Federal Regulations, or any practitioner dispensing narcotic drugs pursuant to section 303(g) of the Controlled Substances Act (21 U.S.C. 823(g)), or any other entity that the Secretary deems appropriate.

changed Co-prescribing—Prescribing— For purposes of this section and section 3, the term co-prescribing “prescribing” means, with respect to an opioid overdose reversal drug, such as naloxone, the practice of prescribing such drug in conjunction with an opioid prescription for patients at an elevated risk of overdose, or in conjunction with an opioid agonist approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) for the treatment of opioid abuse disorders, or in other circumstances in which a provider identifies a patient at an elevated risk for an intentional or unintentional drug overdose from heroin or prescription opioid therapies. For purposes of the previous sentence, a patient may be at an elevated risk of overdose if the patient meets the criteria under the existing co-prescribing guidelines that the Secretary deems appropriate, such as the criteria provided in the Opioid Overdose Toolkit published by the Substance Abuse and Mental Health Services Administration.drug—

changed Use of funds— An eligible entity receiving a grant under this section may use the grant for any of the following activities:activities, but may use not more than 20 percent of the grant funds for activities described in paragraphs (4) and (5):

changed To establish a program for co-prescribing prescribing opioid overdose reversal drugs, such as naloxone.

changed To train and provide resources for health care providers and pharmacists on the co-prescribing prescribing of opioid overdose reversal drugs.drugs, such as naloxone.

changed To purchase opioid overdose reversal drugs drugs, such as naloxone, for distribution under the program described in paragraph (1).

changed To offset the co-pays and other cost sharing associated with opioid overdose reversal drugs drugs, such as naloxone, to ensure that cost is not a limiting factor for eligible patients.

changed To conduct community outreach, in conjunction with community-based organizations, designed to raise awareness of co-prescribing prescribing practices, and the availability of opioid overdose reversal drugs.drugs, such as naloxone.

changed the number of prescribers who have co-prescribed an opioid overdose reversal drugs drug, such as naloxone, to at least one patient;

changed the total number of prescriptions written for opioid overdose reversal drugs;drugs, such as naloxone;

changed the percentage of patients at elevated risk who received a prescription for an opioid overdose reversal drug;drug, such as naloxone;

changed the number of patients reporting use of an opioid overdose reversal drug; drug, such as naloxone; and

changed Reports by Secretary— For each year of the grant program under this section, the Secretary of Health and Human Services shall submit to the appropriate Committees committees of the House of Representatives and of the Senate a report aggregating the information received from the grant recipients for such year under subsection (d) and evaluating the outcomes achieved by the programs funded by grants made under this section.

changed In general— The Not later than 180 days after the date of enactment of this Act, the Secretary of Health and Human Services shall establish a grant program under which the Secretary shall award grants (in this section referred to eligible State entities as the “Secretary”) may, as appropriate, provide information to develop prescribers within Federally qualified health centers (as defined in paragraph (4) of section 1861(aa) of the Social Security Act (42 U.S.C. 1395x(aa))), and the health care facilities of the Indian Health Service, on best practices for prescribing opioid overdose reversal co-prescribing guidelines.drugs, such as naloxone, for patients receiving chronic opioid therapy, patients being treated for opioid use disorders, and other patients that a provider identifies as having an elevated risk of overdose from heroin or prescription opioid therapies.

changed Eligible State entities—Not establishing a medical standard of care— For purposes of subsection (a), eligible State entities are State departments of health in conjunction with State The information on best practices provided under this section shall not be construed as constituting or establishing a medical boards; city, county, and local health departments; and community stakeholder groups involved in reducing standard of care for prescribing opioid overdose deaths.reversal drugs, such as naloxone, for patients described in subsection (a).